Across TCGA pan-cancer cohorts, VPS33B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VPS33B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VPS33B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VPS33B expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and GBM are the cancer types where VPS33B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.325	0.866	.006	14	view →
HNSC	DFS	Quartile	II,III,IV	0.848	0.495	.017	4	view →
GBM	OS	Median	All	0.463	0.633	.037	3	view →
CCRCC	DFS	Median	All	0.859	0.721	.039	2	view →
LSCC	DFS	Median	All	0.891	0.976	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: VPS33B tumor-vs-normal RNA expression · all VPS33B data types